Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Telix Pharmaceuticals ( (AU:TLX) ) has provided an update.
Telix Pharmaceuticals Limited has announced the issuance of 139,741 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX) under the code TLX. This move is part of the company’s strategy to enhance its capital structure and support its ongoing operations, potentially strengthening its position in the biotechnology sector and providing value to its stakeholders.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$26.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited operates in the biotechnology industry, focusing on the development and commercialization of diagnostic and therapeutic products using molecularly targeted radiation. The company primarily targets the oncology market, aiming to improve the diagnosis and treatment of cancer.
Average Trading Volume: 1,612,530
Technical Sentiment Signal: Buy
Current Market Cap: A$8.81B
For detailed information about TLX stock, go to TipRanks’ Stock Analysis page.